<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">FEBS J</journal-id><journal-id journal-id-type="iso-abbrev">FEBS J</journal-id><journal-id journal-id-type="publisher-id">febs</journal-id><journal-title-group><journal-title>The Febs Journal</journal-title></journal-title-group><issn pub-type="ppub">1742-464X</issn><issn pub-type="epub">1742-4658</issn><publisher><publisher-name>Blackwell Publishing Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3892176</article-id><article-id pub-id-type="doi">10.1111/febs.12453</article-id><article-categories><subj-group subj-group-type="heading"><subject>Special Issue</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Phosphoproteomic analysis of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> in neuroblastoma cells </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sattu</surname><given-names>Kamaraj</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hochgräfe</surname><given-names>Falko</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Jianmin</given-names></name><xref ref-type="aff" rid="au3">3</xref><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Umapathy</surname><given-names>Ganesh</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schönherr</surname><given-names>Christina</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ruuth</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chand</surname><given-names>Damini</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Witek</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fuchs</surname><given-names>James</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Pui-Kai</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hugosson</surname><given-names>Fredrik</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Daly</surname><given-names>Roger J</given-names></name><xref ref-type="aff" rid="au3">3</xref><xref ref-type="aff" rid="au6">6</xref></contrib><contrib contrib-type="author"><name><surname>Palmer</surname><given-names>Ruth H</given-names></name><xref ref-type="corresp" rid="cor1"/><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hallberg</surname><given-names>Bengt</given-names></name><xref ref-type="corresp" rid="cor1"/><xref ref-type="aff" rid="au1">1</xref></contrib><aff id="au1"><label>1</label><institution>Department of Molecular Biology, Umeå University</institution><addr-line>Sweden</addr-line></aff><aff id="au2"><label>2</label><institution>Competence Center Functional Genomics, University of Greifswald</institution><addr-line>Germany</addr-line></aff><aff id="au3"><label>3</label><institution>Cancer Research Program, Garvan Institute of Medical Research</institution><addr-line>Sydney, New South Wales, Australia</addr-line></aff><aff id="au4"><label>4</label><institution>St Vincent's Clinical School, Faculty of Medicine, University of New South Wales</institution><addr-line>New South Wales, Australia</addr-line></aff><aff id="au5"><label>5</label><institution>Division of Medicinal Chemistry and Pharmacology, College of Pharmacy, Ohio State University</institution><addr-line>Columbus, OH, USA</addr-line></aff><aff id="au6"><label>6</label><institution>Signalling Network Laboratory, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University</institution><addr-line>Victoria, Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold>, R. Palmer and B. Hallberg, Department of Molecular Biology, Building 6L, Umeå University, Umeå S-901 87, Sweden, Fax: +46 (0) 90 77 26 30, Tel: +46 (0) 90 785 6786; +46 (0) 90 785 2523, E-mail: <email>ruth.palmer@molbiol.umu.se</email>; <email>bengt.hallberg@molbiol.umu.se</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2013</year></pub-date><volume>280</volume><issue>21</issue><fpage>5269</fpage><lpage>5282</lpage><history><date date-type="received"><day>03</day><month>3</month><year>2013</year></date><date date-type="rev-recd"><day>11</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>7</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Federation of European Biochemical Societies</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Activation of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>) receptor tyrosine kinase is a key oncogenic mechanism in a growing number of tumor types. </plain></SENT>
<SENT sid="2" pm="."><plain>In the majority of cases, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> is activated by fusion with a dimerizing partner protein as a result of chromosomal translocation events, most studied in the case of the <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">nucleophosmin</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and echinoderm <z:uniprot sup="inside" fb="0" ids="Q9DCV4">microtubule-associated protein</z:uniprot>-like 4–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> oncoproteins. </plain></SENT>
<SENT sid="3" pm="."><plain>It is now also appreciated that the full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor can be activated by point mutations and by deletions within the extracellular domain, such as those observed in neuroblastoma. </plain></SENT>
<SENT sid="4" pm="."><plain>Several studies have employed phosphoproteomics approaches to find substrates of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> fusion proteins. </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, we used MS-based phosphotyrosine profiling to characterize phosphotyrosine signaling events associated with the full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor. </plain></SENT>
<SENT sid="6" pm="."><plain>A number of previously identified and novel targets were identified. </plain></SENT>
<SENT sid="7" pm="."><plain>One of these, signal transducer and activator of transcription 3 (<z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>), has previously been observed to be activated in response to oncogenic <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling, but the significance of this in signaling from the full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor has not been explored further. </plain></SENT>
<SENT sid="8" pm="."><plain>We show here that activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> robustly activates <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> on Tyr705 in a number of independent neuroblastoma cell lines. </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, knockdown of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> by RNA interference resulted in a reduction in myelocytomatosis neuroblastom (<z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>) protein levels downstream of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling. </plain></SENT>
<SENT sid="10" pm="."><plain>These observations, together with a decreased level of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> and inhibition of neuroblastoma cell growth in the presence of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitors, suggest that activation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> is important for <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling activity in neuroblastoma. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>anaplastic lymphoma kinase</kwd><kwd>cancer</kwd><kwd>neuroblastoma</kwd><kwd>SHP-2</kwd><kwd>signal transducer and activator of transcription 3 (STAT3)</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="11" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Many of the tyrosine kinases in the human kinome are implicated in human cancers 1, and provide important targets for cancer treatment, as well as biomarkers for patient stratification. </plain></SENT>
<SENT sid="13" pm="."><plain>Recently, tyrosine kinase inhibitors targeting <z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>) have been approved for the treatment of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-positive non-small-cell-lung-cancer (NSCLC) 2. </plain></SENT>
<SENT sid="14" pm="."><plain>In NSCLC, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation occurs via chromosomal translocation, leading to activation of the kinase domain. </plain></SENT>
<SENT sid="15" pm="."><plain>However, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> is also known to be mutated in the context of the full-length receptor tyrosine kinase (RTK), this being most clearly understood in neuroblastoma. </plain></SENT>
<SENT sid="16" pm="."><plain>Neuroblastoma is a childhood cancer that stems from the sympathetic nervous system 3, most commonly originating in the adrenal glands, but also developing at additional sites in the neck, chest, and abdomen. </plain></SENT>
<SENT sid="17" pm="."><plain>It is considered to be a disease of developing tissue, as it originates from precursor cells of neural crest tissue that are active during embryonic development 4. </plain></SENT>
<SENT sid="18" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> gain-of-function mutations have been described in both familial 5–6 and sporadic 6–10 neuroblastoma. </plain></SENT>
<SENT sid="19" pm="."><plain>Although there is currently no clinically approved specific treatment for <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> mutations in neuroblastoma, ongoing clinical trials are being conducted to determine the potential usefulness of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-targeted therapies for use in future treatment approaches 11. </plain></SENT>
<SENT sid="20" pm="."><plain>Today, crizotinib (PF-02341066) is in use as a Food and Drug Administration-approved drug for the treatment of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-positive NSCLC 12. </plain></SENT>
<SENT sid="21" pm="."><plain>Clinical studies today suggest that anti-<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> inhibitor therapy offers promise in the treatment of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-mediated tumors 2,11. </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>One consistent problem with kinase inhibitors and their use in a more personalized therapy approach is the drug-resistant mutations that arise in response to treatment, most commonly within the ATP-binding site of the kinase in question. </plain></SENT>
<SENT sid="23" pm="."><plain>Originally described in the <z:uniprot sup="inside" fb="0" ids="P0CY46,P13387,P04412,P00533,P55245,Q01279">epidermal growth factor receptor</z:uniprot> and breakpoint cluster region–c-abl kinase domains 14–18, this has now also been described for echinoderm <z:uniprot sup="inside" fb="0" ids="Q9DCV4">microtubule-associated protein</z:uniprot>-like 4 (<z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>)–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> by Choi et al., and others who have described the appearance of such mutations in the fusion <z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> protein that confers resistance to crizotinib 19–22. </plain></SENT>
<SENT sid="24" pm="."><plain>Phase I/II studies of crizotinib in children with relapsed/refractory tumors involving <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, including neuroblastoma patients, have been initiated (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, NCT01182896) 23. </plain></SENT>
</text></p><p><text><SENT sid="25" pm="."><plain>Given the increasing clinical importance of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activity, we chose to characterize <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-mediated tyrosine kinase signaling networks by MS-based phosphoproteomics. </plain></SENT>
<SENT sid="26" pm="."><plain>In the current study, we conducted a comprehensive profiling of endogenous proteins that are tyrosine-phosphorylated upon expression and activation of wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> in PC12 cells, a cell line originally from the rat neural crest. </plain></SENT>
<SENT sid="27" pm="."><plain>This list, which reflects both direct and indirect tyrosine phosphorylation targets as a result of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activity within the cell, verifies several recently published results such as <z:uniprot sup="inside" fb="0" ids="Q8WU20,Q8C180">fibroblast growth factor receptor substrate 2</z:uniprot> (<z:uniprot sup="inside" fb="1" ids="Q3EBQ3,Q8WU20,P15625">FRS2</z:uniprot>) 23. </plain></SENT>
<SENT sid="28" pm="."><plain>One of the proteins that was most significantly tyrosine-phosphorylated in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation in our analysis was signal transducer and activator of transcription 3 (<z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>), which has previously been reported to be phosphorylated by both the full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> fusion proteins 24–27. </plain></SENT>
<SENT sid="29" pm="."><plain>Here, we investigated this further, and clarified the importance of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> as a mediator in the initiation of transcription of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results"><title><text><SENT sid="30" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="31" pm="."><plain>Phosphotyrosine profiling of PC12 cells expressing <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> </plain></SENT>
</text></title><p><text><SENT sid="32" pm="."><plain>To identify sites with altered phosphorylation associated with <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> RTK activity, we utilized an immunoaffinity-coupled LC-MS/MS approach on PC12 <z:uniprot sup="inside" fb="23" ids="M9NEY8">Tet</z:uniprot>-on-inducible cell lines. </plain></SENT>
<SENT sid="33" pm="."><plain>After induction, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> was activated by addition of agonist mAbs that have previously been reported to initiate <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling pathways 10–28. </plain></SENT>
<SENT sid="34" pm="."><plain>Comparison with controls expressing unstimulated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> allowed quantification of 336 phosphorylation sites (207 phosphotyrosine, 78 phosphoserine, and 51 phosphothreonine) derived from 189 different proteins (Table S1). </plain></SENT>
<SENT sid="35" pm="."><plain>Label-free quantification of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-activated versus control cells revealed 101 phosphorylation sites (73 phosphotyrosine, 13 phosphoserine, and 15 phosphothreonine) in 72 proteins, with a more than five-fold increase in corresponding phosphopeptide intensities. </plain></SENT>
<SENT sid="36" pm="."><plain>In contrast, only 19 phosphorylation sites in 12 proteins were found with decreased phosphorylation following <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> induction. </plain></SENT>
<SENT sid="37" pm="."><plain>Within the list of mapped phosphorylation sites, we identified 11 phosphotyrosine sites that belong to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> (Fig. 1A). </plain></SENT>
<SENT sid="38" pm="."><plain>As expected, all of them showed a significant increase in the level of phosphorylation on activation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> with mAb as compared with control cells (Table S1). </plain></SENT>
<SENT sid="39" pm="."><plain>The identified tyrosine phosphorylation sites in full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> overlap with the predicted ones (PhosphoMotif, Human Protein Reference Database, <ext-link ext-link-type="uri" xlink:href="http://www.hprd.org/PhosphoMotif_finder">http://www.hprd.org/PhosphoMotif_finder</ext-link>), and cover, with only one exception, the entire set of mapped phosphotyrosine sites from earlier investigations of <z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">nucleophosmin</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>)–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> 29,30. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig01" position="float"><label>Figure 1</label><caption><p><text><SENT sid="40" pm="."><plain>(A) Tyrosine residues phosphorylated in the kinase domain of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
<SENT sid="41" pm="."><plain>The intracellular domain of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> containing the protein kinase domain (<z:uniprot sup="inside" fb="0" ids="Q15139">PKD</z:uniprot>) (red) and potential autophosphorylation sites were searched with phosphomotif (<ext-link ext-link-type="uri" xlink:href="http://www.hprd.org/PhosphoMotif_finder">http://www.hprd.org/PhosphoMotif_finder</ext-link>) as indicated. </plain></SENT>
<SENT sid="42" pm="."><plain>Presented and compared side-by-side with our phosphotyrosine mapping of activated full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> are the global surveys of phosphotyrosine peptides identified in <z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> 29,30. </plain></SENT>
<SENT sid="43" pm="."><plain>The critical tyrosines in the activation loop of the kinase domain of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> are boxed 45. </plain></SENT>
<SENT sid="44" pm="."><plain>(B) Protein–protein interactions of human orthologs of the <z:uniprot sup="inside" fb="2" ids="Q9QSP3,Q8JTH2,Q2Y2M5,Q6X1D7,P0C798,P0C799,Q9E787,P33454,P06940,P16380,A7WNB2,O56774,A4UHP9,A4UHQ4,O55778,Q82037,Q8B9Q8,P14156,P24567,P03421,O42062,P12579,Q08454,Q82681,Q5VKP5,Q5K2K6,Q6X1D3,O56773,P35974,Q9WMB4,P03422,P26033,Q00793,Q6E0X0,P0C569,Q5MKM7,P19717,P16072,P16595,P60166,Q9JGU0,P16073,P24698,Q9DLD6,Q06427,Q9IK91,Q83956,P35939,P32530,P28054,P32531,P32532,P23055,P23056,P06163,P06162,P22044,P21738,Q01769,P11208,P15198,Q66T64,P22363,Q0GBX8,P69479,Q8B6J8,A3RM20,P69480,Q9IPJ8,P06747,Q0GBY3,P16286,P35945,Q03335,O70790,P14251,Q9DUE2,P14252,P04859,O57285,P04860,Q9QJT8,Q86606,Q91DS2,P21299,Q5GA89,D8V071,Q9WS39,Q4VKV7,P03520,Q8B0H3,P04879,P04880,Q8B0I3,Q8B0H8,P04878,P04877,Q5VKP1,Q9E7N7">phosphoproteins</z:uniprot> identified in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-expressing PC12 cells. </plain></SENT>
<SENT sid="45" pm="."><plain>In the network, proteins with upregulated phosphorylation sites in activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-expressing PC12 cells as compared with control cells are in red, and proteins with downregulated phosphorylation sites are in green. </plain></SENT>
<SENT sid="46" pm="."><plain>Blue edges indicate protein–protein interactions, and orange edges indicate kinase–substrate relationships. </plain></SENT>
<SENT sid="47" pm="."><plain>Only the network including <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> is shown. </plain></SENT>
<SENT sid="48" pm="."><plain>The pale blue balls indicate (human orthologs of) PC12 proteins with identified/mapped phosphotyrosines that were not found to be significantly regulated. </plain></SENT>
</text></p></caption><graphic xlink:href="febs0280-5269-f1"/></fig></SecTag><p><text><SENT sid="49" pm="."><plain>To highlight potential direct downstream substrates of full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, a network analysis using known protein–protein interactions and experimentally verified kinase–substrate relationships of the human orthologs of the identified <z:uniprot sup="inside" fb="2" ids="Q9QSP3,Q8JTH2,Q2Y2M5,Q6X1D7,P0C798,P0C799,Q9E787,P33454,P06940,P16380,A7WNB2,O56774,A4UHP9,A4UHQ4,O55778,Q82037,Q8B9Q8,P14156,P24567,P03421,O42062,P12579,Q08454,Q82681,Q5VKP5,Q5K2K6,Q6X1D3,O56773,P35974,Q9WMB4,P03422,P26033,Q00793,Q6E0X0,P0C569,Q5MKM7,P19717,P16072,P16595,P60166,Q9JGU0,P16073,P24698,Q9DLD6,Q06427,Q9IK91,Q83956,P35939,P32530,P28054,P32531,P32532,P23055,P23056,P06163,P06162,P22044,P21738,Q01769,P11208,P15198,Q66T64,P22363,Q0GBX8,P69479,Q8B6J8,A3RM20,P69480,Q9IPJ8,P06747,Q0GBY3,P16286,P35945,Q03335,O70790,P14251,Q9DUE2,P14252,P04859,O57285,P04860,Q9QJT8,Q86606,Q91DS2,P21299,Q5GA89,D8V071,Q9WS39,Q4VKV7,P03520,Q8B0H3,P04879,P04880,Q8B0I3,Q8B0H8,P04878,P04877,Q5VKP1,Q9E7N7">phosphoproteins</z:uniprot> was performed (Fig. 1B). </plain></SENT>
<SENT sid="50" pm="."><plain>The network model illustrated two of the identified <z:uniprot sup="inside" fb="2" ids="Q9QSP3,Q8JTH2,Q2Y2M5,Q6X1D7,P0C798,P0C799,Q9E787,P33454,P06940,P16380,A7WNB2,O56774,A4UHP9,A4UHQ4,O55778,Q82037,Q8B9Q8,P14156,P24567,P03421,O42062,P12579,Q08454,Q82681,Q5VKP5,Q5K2K6,Q6X1D3,O56773,P35974,Q9WMB4,P03422,P26033,Q00793,Q6E0X0,P0C569,Q5MKM7,P19717,P16072,P16595,P60166,Q9JGU0,P16073,P24698,Q9DLD6,Q06427,Q9IK91,Q83956,P35939,P32530,P28054,P32531,P32532,P23055,P23056,P06163,P06162,P22044,P21738,Q01769,P11208,P15198,Q66T64,P22363,Q0GBX8,P69479,Q8B6J8,A3RM20,P69480,Q9IPJ8,P06747,Q0GBY3,P16286,P35945,Q03335,O70790,P14251,Q9DUE2,P14252,P04859,O57285,P04860,Q9QJT8,Q86606,Q91DS2,P21299,Q5GA89,D8V071,Q9WS39,Q4VKV7,P03520,Q8B0H3,P04879,P04880,Q8B0I3,Q8B0H8,P04878,P04877,Q5VKP1,Q9E7N7">phosphoproteins</z:uniprot> with increased phosphorylation as potential direct targets of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> following <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> induction, namely <z:uniprot sup="inside" fb="0" ids="Q90687,Q06124">PTPN11</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q06124,P35235,P41499">SHP-2</z:uniprot>) and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>. </plain></SENT>
<SENT sid="51" pm="."><plain>Neither of these has previously been shown to interact with full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
<SENT sid="52" pm="."><plain>In agreement with a role for these proteins downstream of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, we detected approximately 10-fold higher phosphorylation at Tyr546 and Tyr584 in <z:uniprot sup="inside" fb="0" ids="Q06124,P35235,P41499">SHP-2</z:uniprot> as well as Tyr705 in <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> under <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-activating conditions in our model. </plain></SENT>
<SENT sid="53" pm="."><plain>Furthermore, identified downstream targets of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> detected in this phosphoprofiling, such as <z:uniprot sup="inside" fb="0" ids="Q00859">mitogen-activated protein kinase</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="O42781,Q00859,P27638">MAPK</z:uniprot>)1, <z:uniprot sup="inside" fb="0" ids="P27361,Q63844,P21708">MAPK3</z:uniprot> [extracellular signal-related kinase (<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot>)2/1], <z:uniprot sup="inside" fb="0" ids="P49840,Q2NL51,P18265">glycogen synthase kinase-3α</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q00944,Q05397">FAK</z:uniprot>, and <z:uniprot sup="inside" fb="0" ids="P46109">CRKL</z:uniprot> (Table S1), showed decreased phosphorylation upon abrogation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activity in several neuroblastoma cell lines (Fig. S1). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="54" pm="."><plain><z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activates <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in PC12 cells </plain></SENT>
</text></title><p><text><SENT sid="55" pm="."><plain>We subsequently decided to focus in more detail on one of the most prominent hits from the phosphotyrosine proteomics screen, namely <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>. </plain></SENT>
<SENT sid="56" pm="."><plain>As observed in the screen, activation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> resulted in clear phosphorylation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> at Tyr705. </plain></SENT>
<SENT sid="57" pm="."><plain>PC12 cells expressing either doxycycline-inducible wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> or the ALKF1174S mutant were employed to examine <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activation. </plain></SENT>
<SENT sid="58" pm="."><plain>As <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> is still regarded as an orphan receptor, the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor was stimulated with an agonist mAb that has been previously reported to bind and activate <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> in a cell culture model 28,32. </plain></SENT>
<SENT sid="59" pm="."><plain>Interestingly, whereas long-term stimulation of the wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor did lead to visible tyrosine phosphorylation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, this was not prominently observed after 30 min of stimulation, a time point when <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P27361,Q63844,P21708">ERK1</z:uniprot>/2 were highly phosphorylated (Fig. 2A, compare lanes 3 and 4). </plain></SENT>
<SENT sid="60" pm="."><plain>This is in contrast to the robust activation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> observed upon induction of expression of the ALKF1174S mutant (Fig. 2A, compare lanes 3 and 7). </plain></SENT>
<SENT sid="61" pm="."><plain>In both cases, tyrosine phosphorylation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> was abrogated by the addition of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> inhibitor crizotinib (Fig. 2A, compare lanes 4 and 7 with lanes 5 and 8). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig02" position="float"><label>Figure 2</label><caption><p><text><SENT sid="62" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> phosphorylation and interaction with <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> on <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation. </plain></SENT>
<SENT sid="63" pm="."><plain>(A) <z:uniprot sup="inside" fb="23" ids="M9NEY8">Tet</z:uniprot>-on-inducible PC12 cell clones expressing either wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> or the ALKF1174S mutant receptor were employed. </plain></SENT>
<SENT sid="64" pm="."><plain>Protein expression was induced with 1 μg·mL−1 doxycycline, and cells were serum-starved for 24 h prior to stimulation with 1 μg·mL−1 ALK-activating mAb (mAb31) for 30 min or 24 h. </plain></SENT>
<SENT sid="65" pm="."><plain>Whole cell lysates were analyzed by SDS/PAGE, and this was followed by immunoblotting with antibodies against p-ALKY1278, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, p-STAT3Y705, and p-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot>. </plain></SENT>
<SENT sid="66" pm="."><plain>Pan-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> and pan-<z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> antibodies were employed as loading controls. </plain></SENT>
<SENT sid="67" pm="."><plain>(B, C) PC12 cells were transfected with either wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> or the ALKF1174S mutant together with FLAG-tagged <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> prior to stimulation with 1 μg·mL−1 ALK-activating mAb (mAb46) for 24 h, in the presence or absence of 250 nm crizotinib, as indicated. </plain></SENT>
<SENT sid="68" pm="."><plain>Lysates were immunoprecipitated (IP) with either antibody against FLAG (M2) (B) or with antibody against <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> (mAb31) (C), and this was followed by immunoblotting for <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, FLAG, and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, as indicated. </plain></SENT>
<SENT sid="69" pm="."><plain>WCL, whole cell lysate. </plain></SENT>
</text></p></caption><graphic xlink:href="febs0280-5269-f2"/></fig></SecTag><p><text><SENT sid="70" pm="."><plain>To investigate the activation process further, we examined whether an interaction between <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> could occur. </plain></SENT>
<SENT sid="71" pm="."><plain>We were unable to observe an interaction between doxycycline-induced <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and endogenous <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in PC12 cells (data not shown). </plain></SENT>
<SENT sid="72" pm="."><plain>However, an interaction between <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> was observed on immmunoprecipitation of tagged <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, when wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> was transiently cotransfected with FLAG-tagged <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> (Fig. 2B). </plain></SENT>
<SENT sid="73" pm="."><plain>Upon stimulation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, increased interaction between <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> was observed (Fig. 2B, lane 3). </plain></SENT>
<SENT sid="74" pm="."><plain>This interaction was abrogated by addition of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> inhibitor crizotinib (Fig. 2B, lane 4). </plain></SENT>
<SENT sid="75" pm="."><plain>Similarly, on cotransfection of activated ALKF1174S with FLAG-tagged <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, an interaction was observed that was blocked upon addition of crizotinib prior to immunoprecipitation (Fig. 2B, compare lanes 5 and 6). </plain></SENT>
<SENT sid="76" pm="."><plain>Similarly, we were able to observe <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in both wild-type and gain-of-function <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> immunoprecipitates from PC12 cells transiently expressing <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> (Fig. 2C). </plain></SENT>
<SENT sid="77" pm="."><plain>In agreement with our previous observations, the <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> interaction was crizotinib-sensitive (Fig. 2C, compare lanes 3 and 5 with lanes 4 and 6). </plain></SENT>
<SENT sid="78" pm="."><plain>Quantification of independent blots showed clear six-fold to 10-fold increased binding of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> upon stimulation or when a gain-of-function <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> variant was employed (Fig. S2). </plain></SENT>
<SENT sid="79" pm="."><plain>These data suggest that, upon activation, <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> may be recruited to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling complexes. </plain></SENT>
<SENT sid="80" pm="."><plain>However, it is important to note that our attempts to verify this interaction at the level of endogenous proteins in neuroblastoma cell lines have not been successful. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="81" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> is important for <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> expression in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation </plain></SENT>
</text></title><p><text><SENT sid="82" pm="."><plain>Given recent observations that <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> regulates <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> transcription in neuroblastoma cells and collaborates with <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> in neuroblastoma pathogenesis 34–37, we decided to investigate a role for <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in this process. </plain></SENT>
<SENT sid="83" pm="."><plain>Initially, we employed small interfering RNA (siRNA) targeting <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in a number of neuroblastoma cell lines, including <z:uniprot sup="inside" fb="1" ids="Q08432,Q93QC6,P22681,P63503,Q9CBM9,P9WQ82,P9WQ83,O94350,Q5SHW0,P53780,O31632,Q07703,Q83A83,P06721,P44527,P0A4K2,P0C2T9,A2RM21,Q52811,P18949,Q4L332,P43623,P53101">CBL</z:uniprot>-GE, <z:uniprot sup="inside" fb="1" ids="Q08432,Q93QC6,P22681,P63503,Q9CBM9,P9WQ82,P9WQ83,O94350,Q5SHW0,P53780,O31632,Q07703,Q83A83,P06721,P44527,P0A4K2,P0C2T9,A2RM21,Q52811,P18949,Q4L332,P43623,P53101">CBL</z:uniprot>-BAR, <z:uniprot sup="inside" fb="1" ids="Q08432,Q93QC6,P22681,P63503,Q9CBM9,P9WQ82,P9WQ83,O94350,Q5SHW0,P53780,O31632,Q07703,Q83A83,P06721,P44527,P0A4K2,P0C2T9,A2RM21,Q52811,P18949,Q4L332,P43623,P53101">CBL</z:uniprot>-GA and Kelly cells. </plain></SENT>
<SENT sid="84" pm="."><plain>These neuroblastoma cell lines are all <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> gain-of-function in nature, containing either an activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> mutation (ALKR1275Q, <z:uniprot sup="inside" fb="1" ids="Q08432,Q93QC6,P22681,P63503,Q9CBM9,P9WQ82,P9WQ83,O94350,Q5SHW0,P53780,O31632,Q07703,Q83A83,P06721,P44527,P0A4K2,P0C2T9,A2RM21,Q52811,P18949,Q4L332,P43623,P53101">CBL</z:uniprot>-GA; ALKF1174V, <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE; ALKF1174L, Kelly) or overexpressing an <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor with an extracellular domain deletion (<z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BARΔexon 4–12), and express different levels of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> (Fig. S3) 38,39. </plain></SENT>
<SENT sid="85" pm="."><plain>Cell lines were transfected with either scrambled siRNA, two independent siRNAs targeting <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, or a mock control. </plain></SENT>
<SENT sid="86" pm="."><plain>In each cell line tested, the scrambled siRNA transfection did not reduce <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> levels, which were comparable to those in cells with control transfection without siRNA. </plain></SENT>
<SENT sid="87" pm="."><plain>However, upon transfection with specific <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA, all cell lines tested showed reduced levels of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> as compared with the scrambled transfection controls (Fig. 3A–D, top panels, compare lanes 3 and 4 with lane 2). </plain></SENT>
<SENT sid="88" pm="."><plain>Furthermore, a clear reduction in <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels in <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR, <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA and Kelly cells was observed upon treatment with siRNA targeting <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> (Fig. 3A–D, middle panels, compare lanes 3 and 4 with lane 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig03" position="float"><label>Figure 3</label><caption><p><text><SENT sid="89" pm="."><plain>Loss of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> results in reduced <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels. </plain></SENT>
<SENT sid="90" pm="."><plain>Two independent <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNAs (#1 or #2) were employed to downregulate <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> levels in <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE (A), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR (B), Kelly (C) and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA (D) neuroblastoma cell lines. </plain></SENT>
<SENT sid="91" pm="."><plain>Cells were transfected with either control scrambled siRNA, <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA#1 or <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA#2 prior to cell lysis 48 h post-transfection. </plain></SENT>
<SENT sid="92" pm="."><plain>Whole cell lysates were subsequently immunoblotted for <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>, and pan-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> (as loading control), as indicated. </plain></SENT>
<SENT sid="93" pm="."><plain>Lfm, lipofectamine; scC, scramble control. </plain></SENT>
</text></p></caption><graphic xlink:href="febs0280-5269-f3"/></fig></SecTag><p><text><SENT sid="94" pm="."><plain>To further validate these results, we employed a number of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitors, including FLLL32 and STATTIC, which have previously been shown to inhibit <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activation 41,42. </plain></SENT>
<SENT sid="95" pm="."><plain>We investigated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels in <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE, <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR, Kelly and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA neuroblastoma cell lines upon treatment with <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitors (Fig. 4A–D). </plain></SENT>
<SENT sid="96" pm="."><plain>Treatment with either FLLL32 or STATTIC efficiently abrogated the phosphorylation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> without affecting general <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> levels. </plain></SENT>
<SENT sid="97" pm="."><plain>Importantly, whereas these inhibitors blocked <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activity, they did not affect the phosphorylation status of <z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> or <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> itself (Fig. 4A–D, compare lanes 3 and 4 with lane 1). </plain></SENT>
<SENT sid="98" pm="."><plain>In keeping with the results obtained with <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA treatment, both inhibitors reduced <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels (Fig. 4A–D, compare lanes 3 and 4 with lane 1), suggesting that <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> may act between the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor and expression of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>. </plain></SENT>
<SENT sid="99" pm="."><plain>The <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> inhibitor crizotinib was employed as a control, leading to a reduction in the phosphorylation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, expression of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> and phosphorylation of <z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> (Fig. 4A–D, compare lane 2 with lanes 1, 3 and 4). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig04" position="float"><label>Figure 4</label><caption><p><text><SENT sid="100" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activity is required for regulation of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> expression by <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
<SENT sid="101" pm="."><plain>Neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE (A), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR (B), Kelly (C) and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA (D) were starved and treated with either 250 nm crizotinib (24 h), 5 μm FLLL32 (8 h), 5 μm STATTIC (8 h), or control, as indicated. </plain></SENT>
<SENT sid="102" pm="."><plain>After cell lysis, samples were immunoblotted with antibodies against p-ALKY1278, <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>, p-STAT3Y705, and p-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot>. </plain></SENT>
<SENT sid="103" pm="."><plain>Pan-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> antibodies were employed as loading controls. </plain></SENT>
<SENT sid="104" pm="."><plain>Three independent experiments with similar results were performed, and representative blots are shown. </plain></SENT>
</text></p></caption><graphic xlink:href="febs0280-5269-f4"/></fig></SecTag><p><text><SENT sid="105" pm="."><plain>To investigate further whether <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> is involved in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-activated initiation of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> transcription, we employed an MYCNP–<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> assay in two independent neuroblastoma cell lines 36. </plain></SENT>
<SENT sid="106" pm="."><plain>Cells were transfected with MYCNP–<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> reporter or control, and treated with either STATTIC or FLLL32. </plain></SENT>
<SENT sid="107" pm="."><plain>Upon treatment with <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitors, both cell lines showed reduced <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity as compared with untreated cells (Fig. 5A). </plain></SENT>
<SENT sid="108" pm="."><plain>Additionally, we employed quantitative RT-PCR (qRT-PCR) to confirm a role for <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> regulation of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> transcription. </plain></SENT>
<SENT sid="109" pm="."><plain>As controls, we employed primers amplifying part of the coding sequence of ribosomal protein 29 (<z:uniprot sup="inside" fb="0" ids="Q9FJP3,Q9SWI6,P82248,P48161,P47831,Q58DW3,P47914,Q8HXB8,Q95281,P0DJ21,P05747">RPL29</z:uniprot>) or ribosomal protein 19 (<z:uniprot sup="inside" fb="0" ids="P82413,Q3T0W9,D0VWQ5,P84098,Q8HXN9,Q08066,Q5RB99,P0DJ60,O21264">RPL19</z:uniprot>) (Fig. 5B, data not shown). </plain></SENT>
<SENT sid="110" pm="."><plain>Neuroblastoma cell lines treated with STATTIC or FLLL32 for 24 h showed a significant reduction in <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> mRNA levels in comparison with untreated cells (Fig. 5B). </plain></SENT>
<SENT sid="111" pm="."><plain>Thus, pharmacological inhibition of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activity in neuroblastoma cell lines harboring <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> gain-of-function mutations results in reduced transcription of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> mRNA. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig05" position="float"><label>Figure 5</label><caption><p><text><SENT sid="112" pm="."><plain>Inhibition of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> reduces <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> transcription. </plain></SENT>
<SENT sid="113" pm="."><plain>(A) <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">Luciferase</z:uniprot> assay of neuroblastoma cell lines transfected with MYCNP–<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> or empty pGL2 vector as a control (ctrl). </plain></SENT>
<SENT sid="114" pm="."><plain>The neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR were transfected with empty pGL2 (ctrl) or MYCNP–<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot>. </plain></SENT>
<SENT sid="115" pm="."><plain>Cells were then serum-starved, and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> was inhibited with 2.5 μm FLLL32 or STATTIC for 12 h. </plain></SENT>
<SENT sid="116" pm="."><plain>White bars: untreated neuroblastoma cells. </plain></SENT>
<SENT sid="117" pm="."><plain>Gray bars: cells treated with FLLL32. </plain></SENT>
<SENT sid="118" pm="."><plain>Black bars: cells treated with STATTIC. </plain></SENT>
<SENT sid="119" pm="."><plain>Results are presented as relative <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity, where untreated samples transfected with empty pGL2 vector were set to 1. </plain></SENT>
<SENT sid="120" pm="."><plain>(B) qRT-PCR of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> mRNA in neuroblastoma cell lines. </plain></SENT>
<SENT sid="121" pm="."><plain>The neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR were starved and treated with 2.5 μm FLLL32 or STATTIC for 12 h. </plain></SENT>
<SENT sid="122" pm="."><plain>Primers amplifying part of the coding sequence of <z:uniprot sup="inside" fb="0" ids="P82413,Q3T0W9,D0VWQ5,P84098,Q8HXN9,Q08066,Q5RB99,P0DJ60,O21264">RPL19</z:uniprot> (B) or <z:uniprot sup="inside" fb="0" ids="Q9FJP3,Q9SWI6,P82248,P48161,P47831,Q58DW3,P47914,Q8HXB8,Q95281,P0DJ21,P05747">RPL29</z:uniprot> (data not shown) were used to control for differences in cDNA input. </plain></SENT>
<SENT sid="123" pm="."><plain>Relative expression was calculated according to the ΔΔCt relative quantification method. </plain></SENT>
<SENT sid="124" pm="."><plain>Each sample within an experiment was analyzed in duplicate, and the experiment was carried out at least three times. </plain></SENT>
<SENT sid="125" pm="."><plain>White bars: untreated cells. </plain></SENT>
<SENT sid="126" pm="."><plain>Gray bars: cells treated with FLLL32. </plain></SENT>
<SENT sid="127" pm="."><plain>Black bars: cells treated with STATTIC. </plain></SENT>
</text></p></caption><graphic xlink:href="febs0280-5269-f5"/></fig></SecTag></sec><sec><title><text><SENT sid="128" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activity is required for growth and viability of neuroblastoma cells </plain></SENT>
</text></title><p><text><SENT sid="129" pm="."><plain>We then investigated whether <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> is not only important for initiation of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> transcription but also might influence the proliferation of our neuroblastoma cell lines. </plain></SENT>
<SENT sid="130" pm="."><plain>In this analysis, we employed <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE, <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR, Kelly and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA neuroblastoma cell lines, measuring their growth in response to treatment with the <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitor FLLL32 or <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA. </plain></SENT>
<SENT sid="131" pm="."><plain>In all cell lines examined, reduction of endogenous <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> expression levels by siRNA or treatment with the <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitor FLLL32 resulted in a decrease in cell growth as compared with untreated cells (Fig. 6B, D–G) in a similar manner as crizotinib decreased cell growth (Fig. 6A). </plain></SENT>
<SENT sid="132" pm="."><plain>Furthermore, it was clear that treatment of neuroblastoma cell lines with either FLLL32 or crizotinib reduced the phosphorylation status of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> to a similar degree, without increasing cleavage of poly(ADP-ribose) polymerase (<z:uniprot sup="inside" fb="2" ids="P55057,P08469,O50017,P35875,Q11208,P14043">PARP</z:uniprot>), which was used as a measure of apoptosis (Fig. 6C). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="fig06" position="float"><label>Figure 6</label><caption><p><text><SENT sid="133" pm="."><plain>Loss of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> function decreases neuroblastoma cell proliferation. </plain></SENT>
<SENT sid="134" pm="."><plain>(A, B) Neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE (▪), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR (▴), Kelly (‐) and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA (•) were treated with 250 nm crizotinib (A) and 1.5 μm FLLL32 (B) for 5 days. </plain></SENT>
<SENT sid="135" pm="."><plain>Proliferation was analyzed with the resazurin cell proliferation assay. </plain></SENT>
<SENT sid="136" pm="."><plain>Values are reported as fold relative fluorescence from FLLL32-treated cells versus relative fluorescence from untreated cells (♦). </plain></SENT>
<SENT sid="137" pm="."><plain>Results are from three representative experiments, with each experiment performed in triplicate. </plain></SENT>
<SENT sid="138" pm="."><plain>(C) Neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR, <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE, <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA and Kelly were grown on six-well plates with complete growth medium, starved, and treated with 250 nm crizotinib and 1.5 μm FLLL32 for 6 h. </plain></SENT>
<SENT sid="139" pm="."><plain>Cell lysates were immunoblotted with antibodies against p-<z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> and <z:uniprot sup="inside" fb="2" ids="P55057,P08469,O50017,P35875,Q11208,P14043">PARP</z:uniprot>. </plain></SENT>
<SENT sid="140" pm="."><plain>Tubulin was used as a loading control. </plain></SENT>
<SENT sid="141" pm="."><plain>(D–G) <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR (D), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA (E) <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE (F) and Kelly (G) cell lines were transfected with scrambled siRNA (SiC) (▪), <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA#1 (Si1) (▴) or <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA#2 (Si2) (▴) at 0 and 24 h. </plain></SENT>
<SENT sid="142" pm="."><plain>Cell viability was assessed at 0, 3, 4 and 5 days post-transfection, with the resazurin assay. </plain></SENT>
<SENT sid="143" pm="."><plain>Values are reported as fold relative fluorescence from siRNA-transfected cells versus relative fluorescence from control mock-transfected cells. </plain></SENT>
<SENT sid="144" pm="."><plain>Results are from one of three representative experiments, with each experiment performed in triplicate. </plain></SENT>
</text></p></caption><graphic xlink:href="febs0280-5269-f6"/></fig></SecTag></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="145" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="146" pm="."><plain>It is interesting to compare the results of this study with earlier phosphoproteomics analysis on oncogenic <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> fusion proteins, such as <z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> 29,30. </plain></SENT>
<SENT sid="147" pm="."><plain>In terms of phosphorylation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> itself, these studies identified overlapping but not identical sites in the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> intracellular domain. </plain></SENT>
<SENT sid="148" pm="."><plain>Activation of full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> results in phosphorylation of Tyr1278, Tyr1282, and Tyr1283, which lie in the Y′<z:uniprot sup="inside" fb="151" ids="P01114,O42785,P0CQ43,P0CQ42,G0LD36,A0PDV5">RAS</z:uniprot>′YY autophosphorylation motif in the activation loop. </plain></SENT>
<SENT sid="149" pm="."><plain>Although our data do not allow us to comment on the order of phosphorylation within the Y′<z:uniprot sup="inside" fb="151" ids="P01114,O42785,P0CQ43,P0CQ42,G0LD36,A0PDV5">RAS</z:uniprot>′YY motif, they are in agreement with previous studies elucidating the mechanism of phosphorylation 44,45, and further support the use of antibodies against pTyr1278 as an indicator of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation. </plain></SENT>
<SENT sid="150" pm="."><plain>Another site commonly used to denote activation of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor is Tyr1604, which is situated at the C-terminal tail of the receptor, and has been reported to be important for transformation activity and docking of phospholipase Cγ in studies on <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> 47. </plain></SENT>
<SENT sid="151" pm="."><plain>Although antibodies against pTyr1604 are commonly used to assay <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activity, the importance of Tyr1604 in the interaction of phospholipase Cγ with full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> has not been confirmed. </plain></SENT>
<SENT sid="152" pm="."><plain>The identification in this study reinforces the potential importance of this tyrosine in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation. </plain></SENT>
<SENT sid="153" pm="."><plain>Of the phosphorylated tyrosines identified outside of the activation loop, Tyr1507 of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> lies within a consensus <z:uniprot sup="inside" fb="6" ids="P98083">Shc</z:uniprot>-binding site (NPTpY), and has been shown to be critical for interaction of full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> with <z:uniprot sup="inside" fb="6" ids="P98083">Shc</z:uniprot> 23. </plain></SENT>
<SENT sid="154" pm="."><plain>These results are consistent with earlier work on <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> 48. </plain></SENT>
<SENT sid="155" pm="."><plain>The remaining tyrosines that are phosphorylated in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation identified in this study, namely Tyr1078, Tyr1092, Tyr1096, Tyr1131, Tyr1584, and Tyr1586, have been poorly characterized in the context of the full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> RTK, and determination of their significance requires further analysis. </plain></SENT>
<SENT sid="156" pm="."><plain>However, work on the oncogenic <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> fusion proteins implicates these residues in binding of <z:uniprot sup="inside" fb="0" ids="Q28224,P35568,P35569,P35570,Q6P4Y6">IRS-1</z:uniprot> (Tyr1096) 48, and SNT (<z:uniprot sup="inside" fb="1" ids="Q3EBQ3,Q8WU20,P15625">FRS2</z:uniprot>) (Tyr1096 and Tyr1507) 49. </plain></SENT>
<SENT sid="157" pm="."><plain>As well as identifying tyrosine phosphorylation sites in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, we observed phosphorylation of Ser1086, Ser1281 and Thr1597 on <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
<SENT sid="158" pm="."><plain>Although this finding is intriguing, the significance of these phosphorylation events is unclear. </plain></SENT>
<SENT sid="159" pm="."><plain>Although the phosphorylation of RTKs on serine and threonine is well recognized, its role is much less understood than that of tyrosine phosphorylation. </plain></SENT>
<SENT sid="160" pm="."><plain>However, serine/threonine phosphorylation is known to have important regulatory functions for, for example, <z:uniprot sup="inside" fb="0" ids="Q4H3K6,Q95YM9,Q86PM4,Q26614">fibroblast growth factor receptor</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P0CY46,P13387,P04412,P00533,P55245,Q01279">epidermal growth factor receptor</z:uniprot> 50–51, and Kit 52, to name but a few. </plain></SENT>
</text></p><p><text><SENT sid="161" pm="."><plain>Although information on the phosphorylation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> itself in response to activation represented an important part of the information obtained with this phosphoproteomics approach, the identification of candidate molecules phosphorylated in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation was the primary aim of this investigation. </plain></SENT>
<SENT sid="162" pm="."><plain>The list of <z:uniprot sup="inside" fb="2" ids="Q9QSP3,Q8JTH2,Q2Y2M5,Q6X1D7,P0C798,P0C799,Q9E787,P33454,P06940,P16380,A7WNB2,O56774,A4UHP9,A4UHQ4,O55778,Q82037,Q8B9Q8,P14156,P24567,P03421,O42062,P12579,Q08454,Q82681,Q5VKP5,Q5K2K6,Q6X1D3,O56773,P35974,Q9WMB4,P03422,P26033,Q00793,Q6E0X0,P0C569,Q5MKM7,P19717,P16072,P16595,P60166,Q9JGU0,P16073,P24698,Q9DLD6,Q06427,Q9IK91,Q83956,P35939,P32530,P28054,P32531,P32532,P23055,P23056,P06163,P06162,P22044,P21738,Q01769,P11208,P15198,Q66T64,P22363,Q0GBX8,P69479,Q8B6J8,A3RM20,P69480,Q9IPJ8,P06747,Q0GBY3,P16286,P35945,Q03335,O70790,P14251,Q9DUE2,P14252,P04859,O57285,P04860,Q9QJT8,Q86606,Q91DS2,P21299,Q5GA89,D8V071,Q9WS39,Q4VKV7,P03520,Q8B0H3,P04879,P04880,Q8B0I3,Q8B0H8,P04878,P04877,Q5VKP1,Q9E7N7">phosphoproteins</z:uniprot> contains both known and novel <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling components, some of which have been characterized, but the majority of which remain to be investigated for their relevance in both physiological and pathological <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling. </plain></SENT>
<SENT sid="163" pm="."><plain>Of those known candidates, several examples can be briefly mentioned. </plain></SENT>
<SENT sid="164" pm="."><plain>One molecule identified in our screen was <z:uniprot sup="inside" fb="1" ids="Q3EBQ3,Q8WU20,P15625">FRS2</z:uniprot>, which was phosphorylated on Tyr349 in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation. </plain></SENT>
<SENT sid="165" pm="."><plain><z:uniprot sup="inside" fb="1" ids="Q3EBQ3,Q8WU20,P15625">FRS2</z:uniprot> has previously been reported to bind full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, although the binding site is unclear 23. </plain></SENT>
<SENT sid="166" pm="."><plain>Similarly, <z:uniprot sup="inside" fb="0" ids="P46196,P28482,Q5Z9J0">MAPK1</z:uniprot> – which was phosphorylated on Thr183 in this study – has been shown by several groups to be phosphorylated upon stimulation of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor 53. </plain></SENT>
</text></p><p><text><SENT sid="167" pm="."><plain>One of the major tyrosine-phosphorylated proteins identified in this study was <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, which was phosphorylated on Tyr705 in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation. </plain></SENT>
<SENT sid="168" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> has been reported to be phosphorylated downstream of several of the oncogenic <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> fusion proteins 25,27. </plain></SENT>
<SENT sid="169" pm="."><plain>To date, although several articles have reported <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> phosphorylation downstream of full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, the significance of this is unclear 8–56. </plain></SENT>
<SENT sid="170" pm="."><plain>One study of <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> has suggested that oncogenic <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> binds and activates <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> directly via the first tyrosine (Tyr1278) in the Y′<z:uniprot sup="inside" fb="151" ids="P01114,O42785,P0CQ43,P0CQ42,G0LD36,A0PDV5">RAS</z:uniprot>′YY motif of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> 45. </plain></SENT>
<SENT sid="171" pm="."><plain>The crystal structures of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> show that unphosphorylated Tyr1278 interacts with Cys1097 in the N-lobe of the kinase, implying that phosphorylation of Tyr1278 should make a binding site for <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> available, consistent with this hypothesis. </plain></SENT>
<SENT sid="172" pm="."><plain>In this study, we saw clear phosphorylation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> on Tyr705, which is particularly robust in response to oncogenic forms of the full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor, such as ALKF1174S, <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>Δexon 2–3, and <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>Δexon 4–1239,55. </plain></SENT>
<SENT sid="173" pm="."><plain>Although it was not investigated in this study, it would be of interest to examine the importance of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> phosphorylation in neuroblastoma cells harboring a wild-type nonactive <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> receptor. </plain></SENT>
<SENT sid="174" pm="."><plain>This hypothesis is supported by inhibition of the <z:uniprot sup="inside" fb="0" ids="Q8N6Q3">NB1</z:uniprot> neuroblastoma cells lines with crizotinib, which resulted in a loss of pSTAT3Y705, although the significance of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> for cell growth was not discussed 54. </plain></SENT>
<SENT sid="175" pm="."><plain>In light of the activation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> by <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, we also investigated the interaction of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> with <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>. </plain></SENT>
<SENT sid="176" pm="."><plain>Indeed, we observed an interaction of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> with full-length <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> when overexpressed; however, this was not detectable at the level of endogenous proteins, suggesting that care should be taken when interpreting these results. </plain></SENT>
<SENT sid="177" pm="."><plain>It is unclear whether this is because of limitations of the antibodies employed here, or a masking of the epitope by the interaction, or simply a low level of endogenous interaction. </plain></SENT>
<SENT sid="178" pm="."><plain>Although the precise molecular mechanisms underlying <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activation of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> are unknown, it is clear from these studies that loss of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activity, either by RNA interference-mediated knockdown of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> or by addition of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibitors 41,42, reduces the growth and viability of four neuroblastoma lines. </plain></SENT>
<SENT sid="179" pm="."><plain>One key component examined here was the effect of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activity on <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels. </plain></SENT>
<SENT sid="180" pm="."><plain>Recent work has highlighted the cooperative roles of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> in neuroblastoma, with <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> impacting on both the level of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> transcription and the stability of the <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> protein itself 34–37. </plain></SENT>
<SENT sid="181" pm="."><plain>Given these reports, our finding here that <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> is important for changes in <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels in response to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> signaling is significant. </plain></SENT>
<SENT sid="182" pm="."><plain>Indeed, inhibition of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> by addition of inhibitors, or by RNA interference, reduced <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> levels even in the presence of activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
</text></p><p><text><SENT sid="183" pm="."><plain>In conclusion, our phosphoproteomic analysis identifies a number of phosphorylation sites targeted by activation of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> RTK. </plain></SENT>
<SENT sid="184" pm="."><plain>One prominent target identified in this analysis was <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, which we show here is important for the regulation of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> downstream of activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
<SENT sid="185" pm="."><plain>From our investigations, it is also clear that there is a difference between the ability of wild-type <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> to activate <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> and that of oncogenically activated forms of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>. </plain></SENT>
<SENT sid="186" pm="."><plain>The molecular mechanisms underlying this difference are not known, and further work is required to understand this. </plain></SENT>
<SENT sid="187" pm="."><plain>This work suggests that <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> inhibition may be a viable approach in the regulation of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> activity in neuroblastoma cells, and may have potential therapeutic value in the future. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="188" pm="."><plain>Experimental procedures </plain></SENT>
</text></title><sec sec-type="methods"><title><text><SENT sid="189" pm="."><plain>Phosphotyrosine profiling </plain></SENT>
</text></title><p><text><SENT sid="190" pm="."><plain>Tyrosine phosphorylation profiling of PC12 cells expressing human <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> with and without activation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> was undertaken by immunoaffinity purification with P-Tyr-100 (Cell Signaling Technology, Danvers, MA, USA), followed by LC-MS/MS. </plain></SENT>
<SENT sid="191" pm="."><plain>This was performed as previously described 29–57, except that 20 and 0.8 pmol of the stable isotope-labeled phosphotyrosine peptides EH[13C3,15N1-A]LLApYTLGVK and HTDDEMTGpYV[13C3,15N1-A]TR, respectively, were spiked into each cell lysate prior to phosphopeptide purification. </plain></SENT>
<SENT sid="192" pm="."><plain>Mass spectra of two technical replicates were searched against a rat protein database supplemented with the sequence for human <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> (extracted from UniProtKB/TrEMBL ver. 2013_01; 41 749 reviewed and unreviewed sequences) with maxquant version 1.3.0.5. </plain></SENT>
<SENT sid="193" pm="."><plain>Standard settings were used in maxquant (false discovery rate of &lt; 1% at the protein, peptide and modification site levels), except that the ‘match between runs’ function was enabled. </plain></SENT>
<SENT sid="194" pm="."><plain>A list with high-confidence phosphorylation site identifications was generated by filtering the ‘Phospho(STY) sites’ output table for Localization probability &gt; 75% and Score difference &gt; 5. </plain></SENT>
<SENT sid="195" pm="."><plain>Intensity values for phosphorylation sites were normalized between samples by using correction factors based on the intensity values of the phosphotyrosine sites of the heavily labeled peptide standards. </plain></SENT>
<SENT sid="196" pm="."><plain>Changes in intensity ratios between cells with activated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and control cells of ≥ 5 were considered to be significantly altered. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="197" pm="."><plain>Network analysis </plain></SENT>
</text></title><p><text><SENT sid="198" pm="."><plain>Rat–human orthologs were extracted from ensembl. </plain></SENT>
<SENT sid="199" pm="."><plain>The protein–protein interactions among proteins of interest were retrieved from the Protein Interaction Network Analysis platform 58, and substrate–kinase relationships were downloaded from the PhosphoSitePlus database 59. cytoscape 60 was used for visualization of networks. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="200" pm="."><plain>Cell culture </plain></SENT>
</text></title><p><text><SENT sid="201" pm="."><plain>Stable PC12 <z:uniprot sup="inside" fb="23" ids="M9NEY8">Tet</z:uniprot>-on clones expressing human pTTP-<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> (wild type) have been described previously 33–56. </plain></SENT>
<SENT sid="202" pm="."><plain>Stable clones were selected in DMEM containing 10% horse serum (MP Biomedicals, France), 5% tetracycline-screened fetal bovine serum (Thermo Scientific “HyClone”, Belgium), penicillin, streptomycin, l-glutamine, 100 mg·mL−1 G418, and 2 mg·mL−1 puromycin, at 37 °C and 5% CO2. </plain></SENT>
<SENT sid="203" pm="."><plain>The neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA (1p deletion, 11q deletion, 17q gain, ALKR1275Q mutation), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE (<z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>/<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-amplified, ALKF1174V mutation, 1p deletion, 17q gain), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR (amplified <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>/<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>Δexon 4–12, 1p deletion, 17q gain) and Kelly (<z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot>-amplified, ALKF1174L mutation) were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Sigma, Stockholm, Sweden), 100 U·mL−1 penicillin, and 100 μg·mL−1 streptomycin, at 37 °C in humidified air with 5% CO2 38–40. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="204" pm="."><plain>Cell proliferation </plain></SENT>
</text></title><p><text><SENT sid="205" pm="."><plain><z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GA (0.035 × 106 per well), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE (0.025 × 106 per well), <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR (0.05 × 106 per well) and Kelly (0.035 × 106 per well) cells were seeded in collagen-coated 48-well plates overnight, and, starting on the following day, treated with FLLL32 (1.5 μm) for 0–5 days. </plain></SENT>
<SENT sid="206" pm="."><plain>Cell viability was determined at 0–5 days after drug treatment, with 55 μm resazurin (Sigma, Stockholm, Sweden) 61. </plain></SENT>
<SENT sid="207" pm="."><plain>After 2 h at 37 °C, the amount of metabolized resazurin was analyzed as relative fluorescence with an Infinit200 plate reader (TEKAN, Männedorf, Switzerland). </plain></SENT>
<SENT sid="208" pm="."><plain>Results are from one of three representative experiments, with each experiment being performed in triplicate. </plain></SENT>
<SENT sid="209" pm="."><plain>Results are presented as fold relative fluorescence from FLLL32-treated cells versus relative fluorescence from control untreated cells. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="210" pm="."><plain>Cell lysis and immunoblotting </plain></SENT>
</text></title><p><text><SENT sid="211" pm="."><plain>Cells were harvested and lysed as described previously 33–36. </plain></SENT>
<SENT sid="212" pm="."><plain>Samples were boiled in SDS/PAGE sample buffer, and analyzed on SDS/PAGE gel. </plain></SENT>
<SENT sid="213" pm="."><plain>The antibodies used were anti-<z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> (#9132), anti-p-<z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> (Tyr705) (#9145), anti-p-<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> (Tyr1278) (#6941), anti-p-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> (phospho-<z:uniprot sup="inside" fb="7" ids="Q8TCB0">p44</z:uniprot>/42) (#9101), anti-N-<z:uniprot sup="inside" fb="92" ids="Q17103,P10395,P01110,P06295,P0C0N8,P0C0N9,P12523,Q2HJ27,P49032,Q28350,P01109,P68271,P68272,P21438,Q9MZU0,P01106,P49033,B8XIA5,P22555,A1YG22,P23583,Q29031,A2T7L5,Q9MZT8,Q28566,Q9MZT6,Q9MZT7,Q9MZT9">MYC</z:uniprot> (#9405) (all Cell Signaling Technology, MA, USA), anti-FLAG (clone M2, #F3165; Sigma, Stockholm, Sweden), anti-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> (610123; BD Transduction, Stockholm, Sweden), and anti-<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> (mAb135 and mAb31) 10. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="214" pm="."><plain><z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> siRNA transfection </plain></SENT>
</text></title><p><text><SENT sid="215" pm="."><plain>Cells were transfected with siRNA duplexes STAT3VHS40491 (siRNA #1: sense, 5′-GCAGUUUCUUCAGAGCAGGUAUCUU-3′; antisense, 5′-AAGAUACCUGCUCUGAAGAAACUGC-3′) and STAT3VHS40497 (siRNA #2: sense, 5′-CCUGCAAGAGUCGAAUGAAUGUUCUCUAU-3′; antisense, 5′-AUAGAGAACAUUCGACUCUUGCAGG-3′) with Lipofectamine 2000, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). </plain></SENT>
<SENT sid="216" pm="."><plain>After 6 h, the medium was changed to complete medium without antibiotic, and allowed to grow for 24 or 48 h. </plain></SENT>
<SENT sid="217" pm="."><plain>Cells were collected and processed for immunoblotting as described above to determine the levels of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>, <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> and pan-<z:uniprot sup="inside" fb="13" ids="P29323">ERK</z:uniprot> for a loading control. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="218" pm="."><plain>Immunoprecipitation </plain></SENT>
</text></title><p><text><SENT sid="219" pm="."><plain>PC12 cells were transfected with pcDNA3–hALK or pcDNA3–hALKF1174S (0.6 μg per 2 × 106 cells) together with <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot>–FLAG (0.6 μg per 2 × 106 cells) or pcDNA3 (1.2 μg per 2 × 106 cells), with the Amaxa Biosystems (Cologne, Germany) electroporation procedure. </plain></SENT>
<SENT sid="220" pm="."><plain>Cells were harvested, and cell lysates were pretreated with protein G–Sepharose (Sigma), before being incubated with the anti-FLAG M2-coupled protein G–Sepharose beads overnight at 4 °C, washed five times with NaCl/Tris, boiled in sample loading buffer, run on an SDS/PAGE gel, transferred to poly(vinylidene difluoride) membranes, and probed with antibodies as indicated. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="221" pm="."><plain><z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">Luciferase</z:uniprot> assay </plain></SENT>
</text></title><p><text><SENT sid="222" pm="."><plain>Cells (2 × 105) of the neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR were transfected with empty pGL2 (control) or MYCNP–<z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot>, by the use of Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. </plain></SENT>
<SENT sid="223" pm="."><plain>Cells were then serum-starved, and <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> was inhibited by employing 2.5 μm FLLL32 (generated in the laboratory of P.-K. </plain></SENT>
<SENT sid="224" pm="."><plain>Li) or STATTIC (Sigma, St Louis, MO, USA) for 12 h. </plain></SENT>
<SENT sid="225" pm="."><plain>Each sample within an experiment was analyzed in triplicate, and the experiment was carried out three times. </plain></SENT>
<SENT sid="226" pm="."><plain>Results are presented as relative <z:uniprot sup="inside" fb="2" ids="Q01158,P13129,Q26304,Q27757,P08659">luciferase</z:uniprot> activity, where untreated samples transfected with empty pGL2 vector were set to 1. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="227" pm="."><plain>qRT-PCR </plain></SENT>
</text></title><p><text><SENT sid="228" pm="."><plain>The neuroblastoma cell lines <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-GE and <z:uniprot sup="inside" fb="7" ids="Q8N0X4">CLB</z:uniprot>-BAR were starved and treated with 2.5 μm FLLL32 or STATTIC for 12 h. </plain></SENT>
<SENT sid="229" pm="."><plain>RNA was isolated with the NucleoSpin RNA II Kit (Macherey-Nagel, Duren, Germany). </plain></SENT>
<SENT sid="230" pm="."><plain>One microgram of total RNA was reverse-transcribed with the iScript cDNA Synthesis Kit (Bio-Rad, Sundbyberg, Sweden). </plain></SENT>
<SENT sid="231" pm="."><plain>For the PCR amplification in an iCycler iQ5 (Bio-Rad), 25 ng of cDNA was used in a total reaction mixture of 20 μL containing 10 μL of Quantimix Easy SYG Kit (Biotools, Madrid, Spain), 250 nm forward and reverse primers, and 0.08 μL of fluorescein (USB; Affimetrix, Santa Clara, CA, USA). </plain></SENT>
<SENT sid="232" pm="."><plain>Primers amplifying part of the coding sequence of <z:uniprot sup="inside" fb="0" ids="Q9FJP3,Q9SWI6,P82248,P48161,P47831,Q58DW3,P47914,Q8HXB8,Q95281,P0DJ21,P05747">RPL29</z:uniprot> were used to control for differences in cDNA input. </plain></SENT>
<SENT sid="233" pm="."><plain>The following primers were used: human <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> (forward, 5′-ACCACAAGGCCCTCAGTACC-3′; reverse, 5′-TCTCCACAGTGACCACGTCGATTT-3′); human <z:uniprot sup="inside" fb="0" ids="P82413,Q3T0W9,D0VWQ5,P84098,Q8HXN9,Q08066,Q5RB99,P0DJ60,O21264">RPL19</z:uniprot> (forward, 5′-AACACATCCACAAGCTGAAGGCAG-3′; reverse, 5′-TCTTCACGGCGCTTGCGT-3′); and human <z:uniprot sup="inside" fb="0" ids="Q9FJP3,Q9SWI6,P82248,P48161,P47831,Q58DW3,P47914,Q8HXB8,Q95281,P0DJ21,P05747">RPL29</z:uniprot> (forward, 5′-ATGGCCAAGTCCAAGAACCACA-3′; reverse, 5′-TTGGCATTGTTGGCCTGCAT-3′). </plain></SENT>
<SENT sid="234" pm="."><plain>Relative expression was calculated according to the ΔΔCt relative quantification method. </plain></SENT>
<SENT sid="235" pm="."><plain>Each sample within an experiment was analyzed in duplicate, and the experiment was carried out at least three times. </plain></SENT>
<SENT sid="236" pm="."><plain>Results are presented as relative <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> mRNA expression where untreated samples were set to 1. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="237" pm="."><plain>We thank M. </plain></SENT>
<SENT sid="238" pm="."><plain>Vigny for insightful discussion. </plain></SENT>
<SENT sid="239" pm="."><plain>This work was supported by grants from the Swedish Cancer Society (B. </plain></SENT>
<SENT sid="240" pm="."><plain>Hallberg, 12-0722; R. </plain></SENT>
<SENT sid="241" pm="."><plain>H. </plain></SENT>
<SENT sid="242" pm="."><plain>Palmer, 12-0796), the Children's Cancer Foundation (B. </plain></SENT>
<SENT sid="243" pm="."><plain>Hallberg, 11/020, NBCNSDoktoBidr 11/001; R. </plain></SENT>
<SENT sid="244" pm="."><plain>H. </plain></SENT>
<SENT sid="245" pm="."><plain>Palmer, 10/065), the Swedish Research Council (R. </plain></SENT>
<SENT sid="246" pm="."><plain>H. </plain></SENT>
<SENT sid="247" pm="."><plain>Palmer, 621-2011-5181; B. </plain></SENT>
<SENT sid="248" pm="."><plain>Hallberg, 521-2012-2831), the Lions Cancer Society, Umeå (B. </plain></SENT>
<SENT sid="249" pm="."><plain>Hallberg and R. </plain></SENT>
<SENT sid="250" pm="."><plain>H. </plain></SENT>
<SENT sid="251" pm="."><plain>Palmer, LP 12-1946), and the Bundesministerium für Bildung und Forschung (F. </plain></SENT>
<SENT sid="252" pm="."><plain>Hochgräfe, 03Z1CN21). </plain></SENT>
<SENT sid="253" pm="."><plain>K. </plain></SENT>
<SENT sid="254" pm="."><plain>Sattu is a Children's Cancer Foundation fellow (NBCNSPDHEL09/002). </plain></SENT>
<SENT sid="255" pm="."><plain>R. </plain></SENT>
<SENT sid="256" pm="."><plain>J. </plain></SENT>
<SENT sid="257" pm="."><plain>Daly is supported by a Program Grant (535903) from the National Health and Medical Research Council of Australia. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="b1"><text><SENT sid="258" pm="."><plain>Blume-JensenPHunterTOncogenic kinase signallingNature200141135536511357143 </plain></SENT>
</text></ref><ref id="b2"><text><SENT sid="259" pm="."><plain>HallbergBPalmerRHALK and NSCLC: targeted therapy with <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> inhibitorsF1000 Med Rep2011321doi: <ext-link ext-link-type="doi" xlink:href="10.3410/M3-21">10.3410/M3-21</ext-link>22076124 </plain></SENT>
</text></ref><ref id="b3"><text><SENT sid="260" pm="."><plain>MarisJMHogartyMDBagatellRCohnSLNeuroblastomaLancet20073692106212017586306 </plain></SENT>
</text></ref><ref id="b4"><text><SENT sid="261" pm="."><plain>MarisJMRecent advances in neuroblastomaN Engl J Med20103622202221120558371 </plain></SENT>
</text></ref><ref id="b5"><text><SENT sid="262" pm="."><plain>Janoueix-LeroseyILequinDBrugieresLRibeiroAPontualLCombaretVRaynalVPuisieuxASchleiermacherGPierronGSomatic and germline activating mutations of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> kinase receptor in neuroblastomaNature200845596797018923523 </plain></SENT>
</text></ref><ref id="b6"><text><SENT sid="263" pm="."><plain>MosseYPLaudenslagerMLongoLColeKAWoodAAttiyehEFLaquagliaMJSennettRLynchJEPerriPIdentification of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> as a major familial neuroblastoma predisposition geneNature200845593093518724359 </plain></SENT>
</text></ref><ref id="b7"><text><SENT sid="264" pm="."><plain>CarenHAbelFKognerPMartinssonTHigh incidence of DNA mutations and gene amplifications of the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> gene in advanced sporadic neuroblastoma tumoursBiochem J200841615315918990089 </plain></SENT>
</text></ref><ref id="b8"><text><SENT sid="265" pm="."><plain>ChenYTakitaJChoiYLKatoMOhiraMSanadaMWangLSodaMKikuchiAIgarashiTOncogenic mutations of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> kinase in neuroblastomaNature200845597197418923524 </plain></SENT>
</text></ref><ref id="b9"><text><SENT sid="266" pm="."><plain>GeorgeRESandaTHannaMFrohlingSLutherWIIZhangJAhnYZhouWLondonWBMcGradyPActivating mutations in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> provide a therapeutic target in neuroblastomaNature200845597597818923525 </plain></SENT>
</text></ref><ref id="b10"><text><SENT sid="267" pm="."><plain>MartinssonTErikssonTAbrahamssonJCarenHHanssonMKognerPKamarajSSchonherrCWeinmarJRuuthKAppearance of the novel activating F1174S <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> mutation in neuroblastoma correlates with aggressive tumour progression and unresponsiveness to therapyCancer Res2011719810521059859 </plain></SENT>
</text></ref><ref id="b11"><text><SENT sid="268" pm="."><plain>MosseYPLimMSVossSDWilnerKRuffnerKLaliberteJRollandDBalisFMMarisJMWeigelBJSafety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium studyLancet Oncol20131447248023598171 </plain></SENT>
</text></ref><ref id="b12"><text><SENT sid="269" pm="."><plain>KwakELBangY-JCamidgeDRShawATSolomonBMakiRGOuS-HIDezubeBJJãnnePACostaDBAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med20103631693170320979469 </plain></SENT>
</text></ref><ref id="b13"><text><SENT sid="270" pm="."><plain>ButrynskiJED'AdamoDRHornickJLDal CinPAntonescuCRJhanwarSCLadanyiMCapellettiMRodigSJRamaiyaNCrizotinib in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-rearranged inflammatory myofibroblastic tumorN Engl J Med20103631727173320979472 </plain></SENT>
</text></ref><ref id="b14"><text><SENT sid="271" pm="."><plain>CarterTAWodickaLMShahNPVelascoAMFabianMATreiberDKMilanovZVAtteridgeCEBiggsWHIIIEdeenPTInhibition of drug-resistant mutants of <z:uniprot sup="inside" fb="5" ids="P00519,Q00022,P11681,P10447,P00521">ABL</z:uniprot>, KIT, and EGF receptor kinasesProc Natl Acad Sci USA2005102110111101616046538 </plain></SENT>
</text></ref><ref id="b15"><text><SENT sid="272" pm="."><plain>ShahNPNicollJMNagarBGorreMEPaquetteRLKuriyanJSawyersCLMultiple <z:uniprot sup="inside" fb="117" ids="P11274">BCR</z:uniprot>–<z:uniprot sup="inside" fb="5" ids="P00519,Q00022,P11681,P10447,P00521">ABL</z:uniprot> kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell2002211712512204532 </plain></SENT>
</text></ref><ref id="b16"><text><SENT sid="273" pm="."><plain>GorreMEMohammedMEllwoodKHsuNPaquetteRRaoPNSawyersCLClinical resistance to <z:uniprot sup="inside" fb="29" ids="Q43468,O64728">STI</z:uniprot>-571 cancer therapy caused by <z:uniprot sup="inside" fb="117" ids="P11274">BCR</z:uniprot>–<z:uniprot sup="inside" fb="5" ids="P00519,Q00022,P11681,P10447,P00521">ABL</z:uniprot> gene mutation or amplificationScience200129387688011423618 </plain></SENT>
</text></ref><ref id="b17"><text><SENT sid="274" pm="."><plain>KobayashiSBoggonTJDayaramTJannePAKocherOMeyersonMJohnsonBEEckMJTenenDGHalmosBEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811 </plain></SENT>
</text></ref><ref id="b18"><text><SENT sid="275" pm="."><plain>PaoWMillerVAPolitiKARielyGJSomwarRZakowskiMFKrisMGVarmusHAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the <z:uniprot sup="inside" fb="0" ids="P13387,P00533,P55245">EGFR</z:uniprot> kinase domainPLoS Med20052e7315737014 </plain></SENT>
</text></ref><ref id="b19"><text><SENT sid="276" pm="."><plain>ChoiYLSodaMYamashitaYUenoTTakashimaJNakajimaTYatabeYTakeuchiKHamadaTHarutaHEML4–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> mutations in lung cancer that confer resistance to <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> inhibitorsN Engl J Med20103631734173920979473 </plain></SENT>
</text></ref><ref id="b20"><text><SENT sid="277" pm="."><plain>DoebeleRCPillingABAisnerDKutateladzeTGLeATWeickhardtAJKondoKLLindermanDJHeasleyLEFranklinWAMechanisms of resistance to crizotinib in patients with <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> gene rearranged non-small cell lung cancerClin Cancer Res2012181472148222235099 </plain></SENT>
</text></ref><ref id="b21"><text><SENT sid="278" pm="."><plain>KatayamaRKhanTMBenesCLifshitsEEbiHRiveraVMShakespeareWCIafrateAJEngelmanJAShawATTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene <z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>–ALKProc Natl Acad Sci USA20111087535754021502504 </plain></SENT>
</text></ref><ref id="b22"><text><SENT sid="279" pm="."><plain>KatayamaRShawATKhanTMMino-KenudsonMSolomonBJHalmosBJessopNWainJCYeoATBenesCMechanisms of acquired crizotinib resistance in <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-rearranged lung cancersSci Transl Med20124120ra17doi:<ext-link ext-link-type="doi" xlink:href="10.1126/scitranslmed.3003316">10.1126/scitranslmed.3003316</ext-link> </plain></SENT>
</text></ref><ref id="b23"><text><SENT sid="280" pm="."><plain>DegoutinJVignyMGouziJYALK activation induces <z:uniprot sup="inside" fb="6" ids="P98083">Shc</z:uniprot> and <z:uniprot sup="inside" fb="1" ids="Q3EBQ3,Q8WU20,P15625">FRS2</z:uniprot> recruitment: signaling and phenotypic outcomes in PC12 cell differentiationFEBS Lett200758172773417274988 </plain></SENT>
</text></ref><ref id="b24"><text><SENT sid="281" pm="."><plain>ChandDYamazakiYRuuthKSchonherrCMartinssonTKognerPAttiyehEFMarisJMorozovaOMarraMACell and Drosophila model systems define three classes of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> mutations in neuroblastomaDis Models Mechanisms20126373382 </plain></SENT>
</text></ref><ref id="b25"><text><SENT sid="282" pm="."><plain>CrockettDKLinZElenitoba-JohnsonKSLimMSIdentification of <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> interacting proteins by tandem mass spectrometryOncogene2004232617262914968112 </plain></SENT>
</text></ref><ref id="b26"><text><SENT sid="283" pm="."><plain>TanizakiJOkamotoITakezawaKSakaiKAzumaKKuwataKYamaguchiHHatashitaENishioKJannePACombined effect of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> and MEK inhibitors in <z:uniprot sup="inside" fb="0" ids="Q9HC35,Q08A72">EML4</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>-positive non-small-cell lung cancer cellsBr J Cancer201210676376722240786 </plain></SENT>
</text></ref><ref id="b27"><text><SENT sid="284" pm="."><plain>ZamoAChiarleRPivaRHowesJFanYChilosiMLevyDEInghiramiGAnaplastic lymphoma kinase (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>) activates <z:uniprot sup="inside" fb="0" ids="P42227,P52631">Stat3</z:uniprot> and protects hematopoietic cells from cell deathOncogene2002211038104711850821 </plain></SENT>
</text></ref><ref id="b28"><text><SENT sid="285" pm="."><plain>Moog-LutzCDegoutinJGouziJYFrobertYBrunet-de CarvalhoNBureauJCreminonCVignyMActivation and inhibition of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophinJ Biol Chem2005280260392604815886198 </plain></SENT>
</text></ref><ref id="b29"><text><SENT sid="286" pm="."><plain>RikovaKGuoAZengQPossematoAYuJHaackHNardoneJLeeKReevesCLiYGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell20071311190120318083107 </plain></SENT>
</text></ref><ref id="b30"><text><SENT sid="287" pm="."><plain>RushJMoritzALeeKAGuoAGossVLSpekEJZhangHZhaXMPolakiewiczRDCombMJImmunoaffinity profiling of tyrosine phosphorylation in cancer cellsNat Biotechnol2005239410115592455 </plain></SENT>
</text></ref><ref id="b31"><text><SENT sid="288" pm="."><plain>WangPWuFZhangJMcMullenTYoungLCInghamRJLiLLaiRSerine phosphorylation of <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potentialCarcinogenesis20113214615321045017 </plain></SENT>
</text></ref><ref id="b32"><text><SENT sid="289" pm="."><plain>SchonherrCYangHLVignyMPalmerRHHallbergBAnaplastic lymphoma kinase activates the small GTPase <z:uniprot sup="inside" fb="0" ids="Q18246,Q01291">Rap1</z:uniprot> via the <z:uniprot sup="inside" fb="0" ids="Q18246,Q01291">Rap1</z:uniprot>-specific <z:uniprot sup="inside" fb="14" ids="Q9NR83">GEF</z:uniprot> <z:uniprot sup="inside" fb="0" ids="O77086">C3G</z:uniprot> in both neuroblastoma and PC12 cellsOncogene2010292817283020190816 </plain></SENT>
</text></ref><ref id="b33"><text><SENT sid="290" pm="."><plain>YangHLErikssonTVernerssonEVignyMHallbergBPalmerRHThe ligand Jelly Belly (Jeb) activates the Drosophila <z:uniprot sup="inside" fb="0" ids="P97793">Alk</z:uniprot> RTK to drive PC12 cell differentiation, but is unable to activate the mouse <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> RTKJ Exp Zool B Mol Dev Evol200730826928217285636 </plain></SENT>
</text></ref><ref id="b34"><text><SENT sid="291" pm="."><plain>BerryTLutherWBhatnagarNJaminYPoonESandaTPeiDSharmaBVetharoyWRHallsworthAThe <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>(F1174L) mutation potentiates the oncogenic activity of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> in neuroblastomaCancer Cell20122211713022789543 </plain></SENT>
</text></ref><ref id="b35"><text><SENT sid="292" pm="."><plain>HeukampLCThorTSchrammADe PreterKKumpsCDe WildeBOderskyAPeiferMLindnerSSpruesselATargeted expression of mutated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> induces neuroblastoma in transgenic miceSci Transl Med20124141ra91 </plain></SENT>
</text></ref><ref id="b36"><text><SENT sid="293" pm="."><plain>SchonherrCRuuthKKamarajSWangCLYangHLCombaretVDjosAMartinssonTChristensenJGPalmerRHAnaplastic lymphoma kinase (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>) regulates initiation of transcription of <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> in neuroblastoma cellsOncogene2012315193520022286764 </plain></SENT>
</text></ref><ref id="b37"><text><SENT sid="294" pm="."><plain>ZhuSLeeJSGuoFShinJPerez-AtaydeARKutokJLRodigSJNeubergDSHelmanDFengHActivated <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> collaborates with <z:uniprot sup="inside" fb="0" ids="P18444,P04198,Q61976,P26014">MYCN</z:uniprot> in neuroblastoma pathogenesisCancer Cell20122136237322439933 </plain></SENT>
</text></ref><ref id="b38"><text><SENT sid="295" pm="."><plain>SchwabMAlitaloKKlempnauerKHVarmusHEBishopJMGilbertFBrodeurGGoldsteinMTrentJAmplified DNA with limited homology to <z:uniprot sup="inside" fb="92" ids="P06171,P52160,P49709,P06646">myc</z:uniprot> cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumourNature19833052452486888561 </plain></SENT>
</text></ref><ref id="b39"><text><SENT sid="296" pm="."><plain>CazesALouis-BrennetotCMazotPDingliFLombardBBoevaVDaveauRCappoJCombaretVSchleiermacherGCharacterization of rearrangements involving the <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastomaCancer Res20137319520423139213 </plain></SENT>
</text></ref><ref id="b40"><text><SENT sid="297" pm="."><plain>SchleiermacherGJanoueix-LeroseyICombaretVDerreJCouturierJAuriasADelattreOCombined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastomaCancer Genet Cytogenet2003141324212581896 </plain></SENT>
</text></ref><ref id="b41"><text><SENT sid="298" pm="."><plain>WeiCCBallSLinLLiuAFuchsJRLiPKLiCLinJTwo small molecule compounds, LLL12 and FLLL32, exhibit potent inhibitory activity on <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> in human rhabdomyosarcoma cellsInt J Oncol20113827928521109950 </plain></SENT>
</text></ref><ref id="b42"><text><SENT sid="299" pm="."><plain>McMurrayJSA new small-molecule <z:uniprot sup="inside" fb="0" ids="P42227,P52631">Stat3</z:uniprot> inhibitorChem Biol2006131123112417113993 </plain></SENT>
</text></ref><ref id="b43"><text><SENT sid="300" pm="."><plain>SchustJSperlBHollisAMayerTUBergTStattic: a small-molecule inhibitor of <z:uniprot sup="inside" fb="0" ids="P61635,Q6DV79,P40763,Q19S50">STAT3</z:uniprot> activation and dimerizationChem Biol2006131235124217114005 </plain></SENT>
</text></ref><ref id="b44"><text><SENT sid="301" pm="."><plain>Donella-DeanaAMarinOCesaroLGunbyRHFerrareseAColucciaAMTartariCJMologniLScapozzaLGambacorti-PasseriniCUnique substrate specificity of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>): development of phosphoacceptor peptides for the assay of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> activityBiochemistry2005448533854215938644 </plain></SENT>
</text></ref><ref id="b45"><text><SENT sid="302" pm="."><plain>TartariCJGunbyRHColucciaAMSottocornolaRCimbroBScapozzaLDonella-DeanaAPinnaLAGambacorti-PasseriniCCharacterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinaseJ Biol Chem20082833743375018070884 </plain></SENT>
</text></ref><ref id="b46"><text><SENT sid="303" pm="."><plain>WangPWuFMaYLiLLaiRYoungLCFunctional characterization of the kinase activation loop in <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">nucleophosmin</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>)–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> (<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot>) using tandem affinity purification and liquid chromatography–mass spectrometryJ Biol Chem20102859510319887368 </plain></SENT>
</text></ref><ref id="b47"><text><SENT sid="304" pm="."><plain>BaiRYDieterPPeschelCMorrisSWDuysterJNucleophosmin–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicityMol Cell Biol199818695169619819383 </plain></SENT>
</text></ref><ref id="b48"><text><SENT sid="305" pm="."><plain>FujimotoJShiotaMIwaharaTSekiNSatohHMoriSYamamotoTCharacterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)Proc Natl Acad Sci USA199693418141868633037 </plain></SENT>
</text></ref><ref id="b49"><text><SENT sid="306" pm="."><plain>ChikamoriMFujimotoJTokai-NishizumiNYamamotoTIdentification of multiple SNT-binding sites on <z:uniprot sup="inside" fb="0" ids="Q3T160,P16039,P06748,Q61937,P13084,P07222">NPM</z:uniprot>–<z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> oncoprotein and their involvement in cell transformationOncogene2007262950295417086210 </plain></SENT>
</text></ref><ref id="b50"><text><SENT sid="307" pm="."><plain>ZakrzewskaMHaugstenEMNadratowska-WesolowskaBOppeltAHausottBJinYOtlewskiJWescheJWiedlochaAERK-mediated phosphorylation of <z:uniprot sup="inside" fb="0" ids="Q4H3K6,Q95YM9,Q86PM4,Q26614">fibroblast growth factor receptor</z:uniprot> 1 on Ser777 inhibits signalingSci Signal20136ra1123405013 </plain></SENT>
</text></ref><ref id="b51"><text><SENT sid="308" pm="."><plain>KoeseMRenteroCKotaBPHoqueMCairnsRWoodPVila de MugaSReverterMAlvarez-GuaitaAMonastyrskayaKAnnexin A6 is a scaffold for <z:uniprot sup="inside" fb="0" ids="P04409,P17252,P20444,P10102,P05696">PKCalpha</z:uniprot> to promote <z:uniprot sup="inside" fb="0" ids="P13387,P00533,P55245">EGFR</z:uniprot> inactivationOncogene2012322858287222797061 </plain></SENT>
</text></ref><ref id="b52"><text><SENT sid="309" pm="."><plain>Blume-JensenPJiangGHymanRLeeKFO'GormanSHunterTKit/<z:uniprot sup="inside" fb="0" ids="Q28132,Q06220,Q95M19,Q09108,Q90314,P79169,Q95MD2,P21583,P20826,Q95N18,Q29030,P21581,P79368">stem cell factor</z:uniprot> receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertilityNat Genet20002415716210655061 </plain></SENT>
</text></ref><ref id="b53"><text><SENT sid="310" pm="."><plain>PalmerRHVernerssonEGrabbeCHallbergBAnaplastic lymphoma kinase: signalling in development and diseaseBiochem J200942034536119459784 </plain></SENT>
</text></ref><ref id="b54"><text><SENT sid="311" pm="."><plain>BreslerSCWoodACHaglundEACourtrightJBelcastroLTPlegariaJSColeKToporovskayaYZhaoHCarpenterELDifferential inhibitor sensitivity of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P97793">anaplastic lymphoma kinase</z:uniprot> variants found in neuroblastomaSci Transl Med20113108ra114 </plain></SENT>
</text></ref><ref id="b55"><text><SENT sid="312" pm="."><plain>OkuboJTakitaJChenYOkiKNishimuraRKatoMSanadaMHiwatariMHayashiYIgarashiTAberrant activation of <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> kinase by a novel truncated form <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> protein in neuroblastomaOncogene2012314667467622249260 </plain></SENT>
</text></ref><ref id="b56"><text><SENT sid="313" pm="."><plain>SchonherrCRuuthKYamazakiYErikssonTChristensenJPalmerRHHallbergBActivating <z:uniprot sup="inside" fb="0" ids="Q9UM73,P0C586,Q0DDE3">ALK</z:uniprot> mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684Biochem J201144040541321838707 </plain></SENT>
</text></ref><ref id="b57"><text><SENT sid="314" pm="."><plain>HochgrafeFZhangLO'TooleSABrowneBCPineseMPorta CubasALehrbachGMCroucherDRRickwoodDBoulghourjianATyrosine phosphorylation profiling reveals the signaling network characteristics of basal breast cancer cellsCancer Res2010709391940120861192 </plain></SENT>
</text></ref><ref id="b58"><text><SENT sid="315" pm="."><plain>CowleyMJPineseMKassahnKSWaddellNPearsonJVGrimmondSMBiankinAVHautaniemiSWuJPINA v2.0: mining interactome modulesNucleic Acids Res201240D862D86522067443 </plain></SENT>
</text></ref><ref id="b59"><text><SENT sid="316" pm="."><plain>HornbeckPVKornhauserJMTkachevSZhangBSkrzypekEMurrayBLathamVSullivanMPhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouseNucleic Acids Res201240D261D27022135298 </plain></SENT>
</text></ref><ref id="b60"><text><SENT sid="317" pm="."><plain>SmootMEOnoKRuscheinskiJWangPLIdekerTCytoscape 2.8: new features for data integration and network visualizationBioinformatics20112743143221149340 </plain></SENT>
</text></ref><ref id="b61"><text><SENT sid="318" pm="."><plain>O'BrienJWilsonIOrtonTPognanFInvestigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicityEur J Biochem20002675421542610951200 </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="ABBR"><glossary><def-list><def-item><term>ALK</term><def><p>anaplastic lymphoma kinase</p></def></def-item><def-item><term>EML4</term><def><p>echinoderm microtubule-associated protein-like 4</p></def></def-item><def-item><term>ERK</term><def><p>extracellular signal-related kinase</p></def></def-item><def-item><term>MAPK</term><def><p>mitogen-activated protein kinase</p></def></def-item><def-item><term>MYCN</term><def><p>myelocytomatosis neuroblastom</p></def></def-item><def-item><term>NPM</term><def><p>nucleophosmin</p></def></def-item><def-item><term>NSCLC</term><def><p>non-small-cell lung cancer</p></def></def-item><def-item><term>PARP</term><def><p>poly(ADP-ribose) polymerase</p></def></def-item><def-item><term>qRT-PCR</term><def><p>quantitative RT-PCR</p></def></def-item><def-item><term>RPL19</term><def><p>ribosomal protein 19</p></def></def-item><def-item><term>RPL29</term><def><p>ribosomal protein 29</p></def></def-item><def-item><term>RTK</term><def><p>receptor tyrosine kinase</p></def></def-item><def-item><term>siRNA</term><def><p>small interfering RNA</p></def></def-item><def-item><term>STAT3</term><def><p>signal transducer and activator of transcription 3</p></def></def-item></def-list></glossary></SecTag><sec sec-type="supplementary-material"><title/><supplementary-material content-type="local-data" id="SD1"><media mime-subtype="zip" mimetype="application/zip" xlink:href="febs0280-5269-sd1.zip" xlink:type="simple" id="d35e4354" position="anchor"/></supplementary-material></sec></back></article>
